Literature DB >> 31742768

The Accuracy of Prevalent Vertebral Fracture Detection in Children Using Targeted Case-Finding Approaches.

Jinhui Ma1, Kerry Siminoski2, Peiyao Wang3, Nathalie Alos4, Elizabeth A Cummings5, Janusz Feber6, Jacqueline Halton6, Josephine Ho7, Kristin Houghton8, Bianca Lang5, Paivi M Miettunen7, Rosie Scuccimarri9, Jacob L Jaremko10, Khaldoun Koujok11, Brian Lentle12, Mary Ann Matzinger11, Nazih Shenouda11, Frank Rauch9, Leanne M Ward6.   

Abstract

Due to concerns about cumulative radiation exposure in the pediatric population, it is not standard practice to perform spine radiographs in most conditions that predispose to vertebral fracture (VF). In this study we examined the accuracy of two clinical predictors, back pain and lumbar spine bone mineral density (LS BMD), to derive four case-finding paradigms for detection of prevalent VF (PVF). Subjects were 400 children at risk for PVF (leukemia 186, rheumatic disorders 135, nephrotic syndrome 79). Back pain was assessed by patient report, LS BMD was measured by dual-energy X-ray absorptiometry, and PVF were quantified on spine radiographs using the modified Genant semiquantitative method. Forty-four patients (11.0%) had PVF. Logistic regression analysis between LS BMD and PVF produced an odds ratio (OR) of 1.9 (95% confidence interval [CI], 1.5 to 2.5) per reduction in Z-score unit, an area under the receiver operating characteristic curve of 0.70 (95% CI, 0.60 to 0.79), and an optimal BMD Z-score cutoff of -1.6. Case identification using either low BMD alone (Z-score < -1.6) or back pain alone gave similar results for sensitivity (55%, 52%, respectively), specificity (78%, 81%, respectively), positive predictive value (PPV; 24%, 25%, respectively), and negative predictive value (NPV; 93%, 93%, respectively). The paradigm using low BMD plus back pain produced lower sensitivity (32%), higher specificity (96%), higher PPV (47%), and similar NPV (92%). The approach using low BMD or back pain had the highest sensitivity (75%), lowest specificity (64%), lowest PPV (20%), and highest NPV (95%). All paradigms had increased sensitivities for higher fracture grades. Our results show that BMD and back pain history can be used to identify children with the highest risk of PVF so that radiography can be used judiciously. The specific paradigm to be applied will depend on the expected PVF rate and the clinical approach to the use of radiography.
© 2019 American Society for Bone and Mineral Research. © 2019 American Society for Bone and Mineral Research.

Entities:  

Keywords:  CHILDREN; FRACTURE IDENTIFICATION; SENSITIVITY; SPECIFICITY; VERTEBRAL FRACTURE

Mesh:

Year:  2019        PMID: 31742768     DOI: 10.1002/jbmr.3922

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  4 in total

1.  Bone mass and vertebral fractures in South African children on prolonged oral glucocorticoids for chronic non-malignant illnesses.

Authors:  Kebashni Thandrayen; Udai Keshav Kala; Nilesh Lala; Grace Okudo; Kiran Bhagoo Parbhoo; Fatima Yakoub Moosa; Charl Verwey; Marc Hauptfleisch; Christina Hajinicolaou; Priya Ramanlal Ambaram; Bhadrish Jayantkumar Mistry; Karen Lavinia Petersen; John Morley Pettifor
Journal:  Bone Rep       Date:  2021-02-02

Review 2.  Glucocorticoid-Induced Osteoporosis: Why Kids Are Different.

Authors:  Leanne M Ward
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-16       Impact factor: 5.555

3.  Finite element analysis of wedge and biconcave deformity in four different height restoration after augmentation of osteoporotic vertebral compression fractures.

Authors:  Xiao-Hua Zuo; Yin-Bing Chen; Peng Xie; Wen-Dong Zhang; Xiang-Yun Xue; Qian-Xi Zhang; Ben Shan; Xiao-Bing Zhang; Hong-Guang Bao; Yan-Na Si
Journal:  J Orthop Surg Res       Date:  2021-02-15       Impact factor: 2.359

Review 4.  Part I: Which Child with a Chronic Disease Needs Bone Health Monitoring?

Authors:  Leanne M Ward
Journal:  Curr Osteoporos Rep       Date:  2021-07-10       Impact factor: 5.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.